Generics BulletinAs Endo gears up to consummate its $6.7bn merger with Mallinckrodt later this year, the firm has completed the divestment of its International Pharmaceuticals business – primarily operated through Can
Generics BulletinAs Mallinckrodt and Endo continue to work towards merging their businesses, the firms have revealed further details of their plans for the combined company’s generics and sterile injectables unit, whi
In VivoBiopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso
In VivoIn the top alliance by deal value, Zealand Pharma entered into a global collaboration and license agreement with Roche to develop petrelintide, Zealand’s amylin analog as a foundational therapy for we